Ocular disease rates are rising due to an aging population and complications from chronic diseases. Diabetic Retinopathy and Diabetic Macular Edema are common complications of Diabetes, that damage blood vessels in the eye, leading to vision impairment and ultimately blindness.
Effective drug therapies are available, delivered via frequent injections. However, the current process for injecting is unnecessarily complex and time consuming. The current process utilizes generic syringes maladapted for ocular injections, requiring additional accessories and effort, that compromises clinical effectiveness, procedural safety, and patient access to treatment.
We are commercializing the world’s first ocular auto injector, providing a single device for performing effective, safe and efficient ocular injections. The device is designed to transform the complex drug delivery procedure, into a simple injection an ophthalmologist, or their assistants can perform. The device enables clinical efficacy of treatment whilst increasing a clinic’s capacity, improving both patient access and health outcomes.
TTRA Project: Devices
State: NSW
Project Lead: Mr Richard Sokolov
TTRA Funding: $1,200,000.00
Co-Contribution: $1,298,067.76 cash
Project term: 1 July 2025 – 30 June 2027
